Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, Phase 1, randomized, double-blind, placebo-controlled trial in
subjects with moderate to severe psoriasis to assess the safety, tolerability,
immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of multiple
subcutaneous ascending doses of MSB0010841 (Anti-interleukin-17A/F [Anti-IL-17A/F] Nanobody).